imre Health

AMAG Pharmaceuticals

Vyleesi Campaign

It’s the 21st century, and female sexual desire is still a stigmatized health issue. About 1 in 10 women in the U.S. has hypoactive sexual desire disorder (HSDD). But no one was talking about it.

Until Vyleesi.

Launched by AMAG Pharmaceuticals in partnership with imre Health, Vyleesi is the first and only FDA-approved as-needed treatment for premenopausal women with HSDD. To drive condition awareness and reach women where they were online, imre Health led the Vyleesi brand team with a digital-first, consumer-centric integrated campaign that redefined pharma standards.

Combating the shame associated with HSDD isn’t easy. But imre Health embraced pop culture elements to create a brand that was bold, unapologetic, and talked to patients as people first. By using conversational language, the brand campaign, #GHOSTEDbyDesire, gave women the validation to seek help from their doctors with Vyleesi.

And once they received Vyleesi, the packaging maintained the brand experience. A sophisticated design inspired by luxurious beauty products, Vyleesi’s look and feel was able to help reinforce its importance and fit within women’s lives.

Now, Vyleesi is helping to finally destigmatize female sexual health, once and for all.

Agency Team:

Robert Marbury, Creative Director
Cara Peckens, VP, User Experience & Technology
Christina Pandolfi, Associate Creative Director
Robin Sacawa, Senior Program Director
Shadi Ray Jahelka, Designer
Liz Hess, Strategy Manager

Client Team:

Blake Schiller, Executive Director, Vyleesi Marketing
Molly Martin, Director, Consumer Marketing, Vyleesi
Silvio Silva, Senior Product Manager, Vyleesi Consumer Marketing


You May Also Like

ELITE 2020 Drug Researchers and Developers Joshua Cohen and Justin Klee of Amylyx Pharmaceuticals Inc.

Joshua Cohen and Justin Klee Co-Founders and Co-CEOs Amylyx Pharmaceuticals Inc. Potential New Treatment ...

PM360 2020 Innovative Company Curatio

Curatio Jeff Wandzura, Chief Growth Officer The onset of COVID-19 has resulted in ...